AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower ...

AstraZeneca and Daiichi Sankyo have announced that their supplemental Biologics License Application (sBLA) for Enhertu ...

Researchers examined invasive disease-free survival rates at 4 years in a randomized phase 3 trial of adjuvant treatment for ...

The Institute of Cancer Research, London, has uncovered a promising new treatment target for pancreatic cancer, identifying the protein SPP1 as a ...

The pharmaceutical sector has seen a flurry of new deals, partnerships, and drug launches this week, presenting potential ...

Patients receiving ribociclib 400 mg had a shorter QTcF (12.5 vs 19.7 ms at cycle 1 day 15, 2 hours post-dose) and a lower rate of grade 3 or 4 neutropenia (41% vs 58.5%); they were also less likely ...

Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer: Cambridge, UK Thursday, September 25, 2025, 0 ...

The deal involves an upfront payment of $18 million, followed by regulatory and commercial milestone payments of up to $1.093 ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults ...

Patients on Enhertu and Perjeta lived more than three years without disease progression compared to just over two years on Perjeta, Herceptin, and chemo.

The Organisation for Economic Co-operation and Development marginally raised its 2025 growth projection for the UK economy to 1.4% from 1.3%, noting that front‑loading ahead of higher tariffs globally ...